Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Rallybio Holdings LLC RLYB

Healthcare Biotechnology
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for... see more

Current News (NDAQ:RLYB)

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Business Wire November 6, 2025

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Business Wire September 25, 2025

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Business Wire September 3, 2025

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Business Wire August 7, 2025

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Business Wire July 8, 2025

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Business Wire June 12, 2025

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Business Wire May 8, 2025

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

Business Wire April 29, 2025

Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT

Business Wire April 8, 2025
View More News ››

Opinion & Analysis (NDAQ:RLYB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RLYB)

Rallybio Corporation (NASDAQ:RLYB): A Promising Rare Disease

http://beyondspx.com/2024/07/31/rallybio-corporation-nasdaqrlyb-a-promising-rare-disease-biotech-with-multiple-clinical-stage-assets-2/
MikeTester - August 2, 2024
View more Bullboard ››

AE Fuels Corporation

AE Fuels Corporation

AE Fuels Corporation (TSXV: AEF) is a battery materials company focused on the extraction and purification of minerals ...
View More »

Podcasts